BigOmics Analytics, a Swiss biodata analytics startup, announces raising additional funding from Eppendorf, a leading life science company that develops and sells instruments, consumables and services for liquid, sample and cell handling in laboratories worldwide. The additional funding brings the total amount raised so far to CHF 2.7M. It will be used to further develop BigOmics’ platforms, to expand its team and to grow its presence in the market.
The strategic investment was initiated and carried out by the Eppendorf Innovation Company (EpIC), which serves as Eppendorf’s interface for innovative startups. Upon signing the agreement, Peter Fruhstorfer, Co-CEO of Eppendorf SE, commented: “We’re excited to invest in BigOmics, with its expertise and digital know-how, the company is a perfect fit for Eppendorf and our ambition to improve work processes in the lab and set them up for the future. BigOmics and Eppendorf share the goal of accelerating digitalization in life science laboratories to make everyday research workflows simpler, safer, more efficient and faster.”
BigOmics’ vision is to fast-track omics data analysis and significantly reduce discovery time and R&D overhead costs in the field of data-driven therapeutics and precision medicine. Its governed self-service analytics platforms enable biologists and bioinformaticians to communicate interactively instead of exchanging static reports. With these platforms, bioinformaticians can delegate part of their routine work to biologists and let them analyze and interpret their data efficiently through an easy-to-use interface, thus allowing bioinformaticians to focus on more bespoke analyses. It represents a win-win proposition for both biologists and bioinformaticians and balances data quality and analysis agility.
BigOmics’ flagship platform, Omics Playground, supports life scientists with the visualization and analysis of transcriptomics and proteomics data. The cloud nature of the platform makes it easy to access and assist the data analysis needs of users worldwide. To date, BigOmics has closed six enterprise subscriptions with Biotech/Pharma companies and academic labs.
Dr. Murodzhon Akhmedov, CEO and co-founder of BigOmics, said: “It is clear that end-to-end digitized solutions from sample preparation to data acquisition to analysis will bring the greatest value proposition to life scientists. As BigOmics, we are excited to work with Eppendorf towards the same goal and to contribute specifically to data analysis by providing researchers with intelligent tools to perform complex analyses efficiently.” Adding “Thanks to Eppendorf's commitment, we will focus on commercializing our platforms and achieving greater market traction.”
Dr. Ivo Kwee, CTO and co-founder, added: “We want to build the most user-friendly, secure, scalable and interoperable SaaS platforms for the visual analysis of omics data. Eppendorf’s investment will help us expand our team, improve our products and increase the user base.”